Vor Biopharma's $4 Billion Investment Paves Way For Multi-Billion Dollar Autoimmune Market

H.C. Wainwright upgraded Vor Biopharma Inc. (NASDAQ:VOR), highlighting the company’s “rebirth” following the in-licensing of telitacicept. On Thursday, the company announced a strategic licensing agreement and a major capital raise to support its push into autoimmune therapies. Vor Bio signed an…